Need to re-examine treatment-resistant schizophrenia, clozapine use


The positioning of the atypical antipsychotic clozapine as a third-line treatment warrants re-examination since this has led to its underutilization in patients with treatment-refractory schizophrenia, according to a new Canadian review (Agid et al. Can J Psychiatry 2010; 55: 677-684).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page